Trends in Medicare Spending and Utilization of Oral Medications for Clostridioides difficile Infection From 2013 to 2021

被引：1

作者：

Ying, Xiaohan

Gogokhia, Lasha

Jesudian, Arun b.

Zhang, Lillian

Crawford, Carl v ^{[1
]}

机构：

[1] Weill Cornell Med, Div Gastroenterol & Hepatol, 1283 York Ave,9th Floor, New York, NY 10065 USA

来源：

GASTRO HEP ADVANCES | 2024年 / 3卷 / 02期

关键词：

HEALTH-CARE EPIDEMIOLOGY; DISEASES SOCIETY; AMERICA IDSA; FIDAXOMICIN; VANCOMYCIN; GUIDELINES; UPDATE;

D O I：

10.1016/j.gastha.2023.11.010

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：210 / 211

页数：2

共 10 条

[1] Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection [J].

Chen, Jiahe ;

Gong, Cynthia L. ;

Hitchcock, Matthew M. ;

Holubar, Marisa ;

Deresinski, Stanley ;

Hay, Joel W. .

CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (10) :1448-1454

[2] Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged >= 60 years (EXTEND): analysis of cost-effectiveness [J].

Cornely, Oliver A. ;

Watt, Maureen ;

McCrea, Charles ;

Goldenberg, Simon D. ;

De Nigris, Enrico .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (09) :2529-2539

[3] Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial [J].

Cornely, Oliver A. ;

Crook, Derrick W. ;

Esposito, Roberto ;

Poirier, Andre ;

Somero, Michael S. ;

Weiss, Karl ;

Sears, Pamela ;

Gorbach, Sherwood .

LANCET INFECTIOUS DISEASES, 2012, 12 (04) :281-289

[4] Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials [J].

Crook, Derrick W. ;

Walker, A. Sarah ;

Kean, Yin ;

Weiss, Karl ;

Cornely, Oliver A. ;

Miller, Mark A. ;

Esposito, Roberto ;

Louie, Thomas J. ;

Stoesser, Nicole E. ;

Young, Bernadette C. ;

Angus, Brian J. ;

Gorbach, Sherwood L. ;

Peto, Timothy E. A. .

CLINICAL INFECTIOUS DISEASES, 2012, 55 :S93-S103

[5] Trends in US Burden of Clostridioides difficile Infection and Outcomes [J].

Guh, Alice Y. ;

Mu, Yi ;

Winston, Lisa G. ;

Johnston, Helen ;

Olson, Danyel ;

Farley, Monica M. ;

Wilson, Lucy E. ;

Holzbauer, Stacy M. ;

Phipps, Erin C. ;

Dumyati, Ghinwa K. ;

Beldavs, Zintars G. ;

Kainer, Marion A. ;

Karlsson, Maria ;

Gerding, Dale N. ;

McDonald, L. Clifford .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (14) :1320-1330

[6] Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States [J].

Jiang, Yiling ;

Sarpong, Eric M. ;

Sears, Pamela ;

Obi, Engels N. .

INFECTIOUS DISEASES AND THERAPY, 2022, 11 (01) :111-126

[7]

Johnson S, 2021, CLIN INFECT DIS, V73, pE1029, DOI 10.1093/cid/ciab549

[8] Fidaxomicin versus Vancomycin for Clostridium difficile Infection [J].

Louie, Thomas J. ;

Miller, Mark A. ;

Mullane, Kathleen M. ;

Weiss, Karl ;

Lentnek, Arnold ;

Golan, Yoav ;

Gorbach, Sherwood ;

Sears, Pamela ;

Shue, Youe-Kong .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (05) :422-431

[9]

McDonald LC, 2018, CLIN INFECT DIS, V66, pE1, DOI [10.1093/cid/cix1085, 10.1093/cid/ciy149]

[10] Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study [J].

Polivkova, Sylvia ;

Krutova, Marcela ;

Capek, Vaclav ;

Sykorova, Blanka ;

Benes, Jiri .

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 103 :226-233

← 1 →